ArticleHuman genetics1990
Viral integration, fragile sites, and proto-oncogenes in human neoplasia.
Article in Human genetics, 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 93 citations in OpenAlex.
- Unlocking Genome Editing: Advances and Obstacles in CRISPR/Cas Delivery Technologies.Journal of functional biomaterials · 2024Review
- Article
- Gene Editing in Hematopoietic Stem Cells.Advances in experimental medicine and biology · 2023Review
- Advances in CRISPR Delivery Methods: Perspectives and Challenges.The CRISPR journal · 2022Review
- CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson's Disease.Pharmaceutics · 2022Review
- New Era of Mapping and Understanding Common Fragile Sites: An Updated Review on Origin of Chromosome Fragility.Frontiers in genetics · 2022Review
- Comparison of the Feasibility, Efficiency, and Safety of Genome Editing Technologies.International journal of molecular sciences · 2021Review
- Recent Advances in CRISPR/Cas9 Delivery Strategies.Biomolecules · 2020Review
- Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges.Expert opinion on drug delivery · 2018Review
- Virus and host genomic, molecular, and cellular interactions during Marek's disease pathogenesis and oncogenesis.Poultry science · 2016Review
- Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review).International journal of oncology · 2012Review
- Lymphoproliferative Lesions in the Setting of HIV Infection: A Five-Year Retrospective Case Series and Review.Pathology research international · 2011Article
- Article
- Fragile site orthologs FHIT/FRA3B and Fhit/Fra14A2: evolutionarily conserved but highly recombinogenic.Proceedings of the National Academy of Sciences of the United States of America · 2003Article
- Preferential integration of human papillomavirus type 18 near the c-myc locus in cervical carcinoma.Oncogene · 2003Article
- Common fragile sites are preferential targets for HPV16 integrations in cervical tumors.Oncogene · 2003Article
- Article
- Replication delay along FRA7H, a common fragile site on human chromosome 7, leads to chromosomal instability.Molecular and cellular biology · 2000Article
- Molecular characterization of a common fragile site (FRA7H) on human chromosome 7 by the cloning of a simian virus 40 integration site.Proceedings of the National Academy of Sciences of the United States of America · 1998Article
- Adenovirus type 12-induced fragility of the human RNU2 locus requires p53 function.Journal of virology · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the trend of viral integration in the human genome, chromosomal localization of five DNA-containing viruses compiled from literature data was compared to the location of fragile sites and proto-oncogenes. A total of 35 regionally mapped viral integration sites from tumors and transformed cells were distributed over 19 chromosomes. Of the 35 integration sites 23 (66%) were at the bands of fragile sites, and 7 were one band away (20%). This statistically defines the correlation as highly significant (P = 0.0000183, Fisher's F-test). Five integration sites did not correspond to the location of a fragile site. Thirteen integration sites and proto-oncogenes mapped at the same bands (37%), 6 (17%) were one band apart, and at 16 integration sites (46%) no proto-oncogenes were localized (P = 0.00491). Eighteen viral integration sites, fragile sites, and proto-oncogenes (51%) were localized at the same bands or one band distant. This clustering of viral integration sites, fragile sites, and proto-oncogenes is statistically highly significant (P = 0.0000118), and indicates nonrandom viral integration in the human genome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.